18F-Fluciclovine, 68Ga-PSMA, and 18F-DCFPyL PET/CT are currently approved by the Food and Drug Administration (FDA) for men with suspected prostate cancer recurrence, but worldwide approval and funding awaits evidence of improved patient outcomes. This evidence concerns the gene FOLH1 and prostate cancer.